Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Introduces Updated Designer Drug and Oral Fluid Compendiums

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
Webinars to highlight new applications for LC/MS, MS.

Agilent Technologies Inc. has introduced new application compendiums on designer drug testing and toxicology of oral fluids.

Also available is an expanded GC/MS Designer Drug Library. The only resource of its kind, this searchable library includes designer stimulants that are often marketed as "bath salts" as well as additional cannabinoid compounds.

In tandem with the release of these new resources, Agilent is sponsoring monthly webinars featuring industry experts who will discuss new LC/MS and MS applications for forensic detection and analysis of designer drugs and metabolites.

"Designer drugs-especially bath salts-continue to make headlines across the country," said Tom Gluodenis, Agilent's global marketing manager of Forensics and Toxicology.

Gluodenis continued, "The important resources we're introducing today, used in collaboration with our specialized GC/MS laboratory technologies, provide forensic practitioners, crime laboratories, and federal workplace drug-testing programs with cost-effective, end-to-end solutions for designer drug screening and analysis."

Designer drugs are formulated to get around existing definitions of illicit compounds. Once difficult to trace, these substances can now be quickly identified and analyzed using Agilent's GC/MS technologies.

Agilent's expanded application compendium, "Identification of Synthetic Cannabinoids in Herbal Incense Blends by GC/MS," contains information on 45 cannabinoids and describes how to facilitate rapid screening and identification of these marijuana-like compounds. A companion compendium, "Analysis of Designer Stimulants by GC/MS," describes the analysis of 30 stimulants.

Agilent developed these compendiums, and the expanded GC/MS Designer Drug Library, in collaboration with NMS Labs.

Screening oral fluid is an accurate and effective alternative to screening urine or blood. It provides many collection advantages, and samples can be more easily analyzed using highly sensitive enzyme immunoassays and LC-MS/MS instrumentation.

Agilent's updated oral fluid compendium, "Drugs and Metabolites in Oral Fluid: Immunoassay Screening and LC/MS/MS Confirmation and Quantification," is a comprehensive treatise on the detection of drugs of abuse in oral fluid, covering 100 drugs in 11 classes.

The compendium includes information on sample collection and preparation, immunoassay screening and LC/QQQ confirmation. It also reflects changes to the mandatory guidelines for Federal Workplace Drug Testing Programs, and contains protocols for all the newly recommended Schedule II prescription medications. Agilent developed the compendium in collaboration with Immunalysis Corp.

To download the application compendium "Drugs and Metabolites in Oral Fluid," visit Agilent's Forensics & Toxicology website.

Webinar Series for Forensic Practitioners

Throughout the year, Agilent will sponsor a monthly online educational series focusing on the analysis of designer drugs and drugs of abuse. Hosted by RTI International's online education service on www.ForensicEd.org, the webinars listed below will also be available for replay following the live events. Additional webinars will be announced at a later date.

Comprehensive Workflow for Screening and Confirmation of Drugs in Oral Fluids, now accessible for replay at Forensic Science Education: Dr. Christine Moore of Immunalysis Corp. discusses designer drug compendiums, oral fluids sample collection, preparation, drug extraction, immunoassay screening and LC/QQQ confirmation equipment.

LC/QQQ Screening for 300 Designer Drugs and Metabolites, Tuesday, Feb. 26 at 9 a.m. and 1 p.m. EST: Dr. Tony DiCaprio of Florida International University's-, Forensic Science Institute will describe current work focusing on the development of LC-QQQ-MS/MS-based methods for rapid screening of designer drugs in forensic analysis.

GC/MS and GC/QQQ Screening for 300 Designer Drugs and Metabolites, Thursday, April 18 at 9 a.m. and 1 p.m. EST: Dr. Jose Almirall, also of Florida International University's Forensic Science Institute, will focus on the expanded Designer Drug Library that FIU has developed in partnership with Agilent; discussion will also focus on the entire workflow for effective and rapid screening of designer drugs.

Webinar co-sponsor RTI International is the Center of Excellence for the United States National Institute of Justice. The upcoming webinars are part of RTI's specialized forensic education service, which provides online forensic science training and continuing education courses to practitioners in forensic science, law enforcement, medico-legal death investigation and forensic toxicology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent Reports Fourth-Quarter Results
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.
Monday, November 18, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Collaborating with Florida International University
Collaboration to further advance the identification and characterization of designer drugs.
Tuesday, February 26, 2013
Agilent Technologies and Ameritox Form Collaboration
Agilent Technologies Inc. and AmeritoxSM announced that they have formed a research collaboration that could accelerate analysis in the field of medication monitoring.
Tuesday, February 12, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies Reports Second-Quarter 2012 Results
Third-quarter fiscal year 2012 revenue guidance of $1.77 billion - $1.79 billion and non-GAAP earnings guidance of $0.82 - $0.84 per share.
Wednesday, May 16, 2012
Agilent and Integrated Diagnostics Enter Strategic Partnership
The partnership will develop protein-based assays for early disease detection.
Wednesday, January 11, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies and A*STAR’s ETC Launch All-in-One Drug-Screening Platform at Singapore Screening Centre
Agilent to provide a full spectrum of automation technologies to biomedical researchers, enabling highly efficient drug screening in one location.
Tuesday, August 02, 2011
Scientific News
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
Electrical Control of Cancer Cells
Research led by scientists at The University of Texas Health Science Center at Houston (UTHealth) has revealed a new electrical mechanism that can control these switches.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Inflammation Linked to Colon Cancer Metastasis
A new Arizona State University research study led by Biodesign Institute executive director Raymond DuBois has identified for the first time the details of how inflammation triggers colon cancer cells to spread to other organs, or metastasize.
Structural Discoveries Could Aid in Better Drug Design
Scientists have uncovered the structural details of how some proteins interact to turn two different signals into a single integrated output.
Determining the Age of Fingerprints
Watch the imprint of a tire track in soft mud, and it will slowly blur, the ridges of the pattern gradually flowing into the valleys. Researchers have tested the theory that a similar effect could be used to give forensic scientists a way to date fingerprints.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Surprising Mechanism Behind Antibiotic-Resistant Bacteria Uncovered
Now, scientists at TSRI have discovered that the important human pathogen Staphylococcus aureus, develops resistance to this drug by “switching on” a previously uncharacterized set of genes.
Tissue Bank Pays Dividends for Brain Cancer Research
Checking what’s in the bank – the Brisbane Breast Bank, that is – has paid dividends for UQ cancer researchers.
Researchers Publish Landmark “Basket Study”
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations in patients’ tumors rather than where their cancer originated.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!